Table 1.

Summary of cost-effective analyses for SGLT2 inhibitors

Sodium-Glucose Cotransporter 2 Inhibitor	Disease	Country	Annual Cost of Druga	Incremental Cost-Effectiveness Ratio/Quality-Adjusted Life Year Gained	Sensitivity Analyses Highlights
Canagliflozin	Diabetic kidney disease	England	$610b	Cost savings (5)	Alteration to time horizons (5, 10, 20, and 40 yr) changed the degree of cost savings
Dapagliflozin	Nondiabetic kidney disease	United States	$4416	$60,000 (6)	Drug acquisition cost and baseline therapy cost have the biggest effect on cost-effectiveness Variation in cost of dapagliflozin could result in an ICER above a cost-effectiveness threshold of $100,000
Empagliflozin	Diabetic kidney disease	United States	$6360	$25,974 (7) (the cost of standard therapy was assumed to be $0, and thus, the ICER is likely conservative)	Drug acquisition cost and alternative time horizons were top contributors to cost-effectiveness
Dapagliflozin	Diabetic and nondiabetic kidney disease	United Kingdom, Germany, Spain	$665, $898, $477	$8280, $17,623, $35,503 (3)	Drug acquisition cost, background cost of CKD management, and discontinuation rate were top contributors to cost-effectiveness
Dapagliflozin	Diabetic and nondiabetic kidney disease	Thailand	$469	Cost saving (8)	Use in CKD 3b and 4 stages yielded a lower ICER, but the value was still below the accepted local threshold of $5169/QALY

ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.

^aApproximated from the monthly pricing used in the original papers.

^bConverted into US dollars at a rate of 1.28 US dollars per British pound on the basis of the average exchange rate reported in 2019.